Kazem Mahmoud

Dr. Kazem Mahmoud

Egyptian Russian University, Cairo, Al Qāhirah, Egypt
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
Kazem MahmoudKazem Mahmoud
Kazem Mahmoud
MKMartin Krug
Martin Krug
TWTom Wersig
Tom Wersig
ISInna Slynko
Inna Slynko
CSChristoph Schächtele
Christoph Schächtele
AHAndreas Prof. Dr. Hilgeroth
Andreas Prof. Dr. Hilgeroth

1 January 2015 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MSMardia El Sayed
Mardia El Sayed
KAKhadiga M. Ahmed
Khadiga M. Ahmed
Kazem MahmoudKazem Mahmoud
Kazem Mahmoud
AHAndreas Hilgeroth
Andreas Hilgeroth

10 October 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MFMariam Medhat Fakhry
Mariam Medhat Fakhry
Kazem MahmoudKazem Mahmoud
Kazem Mahmoud
MNMohamed S. Nafie
Mohamed S. Nafie
ANAhmad Noor
Ahmad Noor
RHRawan Hareeri
Rawan Hareeri
SKSafaa M. Kishk
Safaa M. Kishk
Breast cancer is a disease in which cells in the breast divide continuously without control. There are great limitations in cancer chemotherapy. Hence, it is essential to search for new cancer therapeutics. Herein, a novel series of EGFR/HER2 dual inhibitors has been designed based on the hybridization of thiazole and pyrazoline fragments. The synthesized compounds were screened for their anti-proliferative activity against MCF-7 breast cancer cell line and MCF-10 normal breast cell line. Interestingly, synthesized compounds 6e and 6k showed very potent antiproliferative activity towards MCF-7 with IC50 values of 7.21 and 8.02 µM, respectively. Furthermore, enzymatic assay was performed against EGFR and HER2 to prove the dual inhibitory action. Compounds 6e and 6k showed potent inhibitory activity for EGFR with IC50 of 0.009 and 0.051 µM, respectively, and for HER2 with IC50 of 0.013 and 0.027 µM, respectively. Additionally, compounds 6e and 6k significantly stimulated apoptotic breast cancer cell death. Compound 6e was further explored for its anticancer activity in vivo using a Xenograft model. Moreover, computational modeling studies, ADMET studies and toxicity prediction were performed to investigate their potential drug candidates.

14 February 2023 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Ahmed H.E. HassanAhmed H.E. Hassan
Ahmed H.E. Hassan
Kazem MahmoudKazem Mahmoud
Kazem Mahmoud
TPTrong-Nhat Phan
Trong-Nhat Phan
MSMoataz A. Shaldam
Moataz A. Shaldam
CLChae Hyeon Lee
Chae Hyeon Lee
YLYong Sup Lee
Yong Sup Lee

11 November 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
WZWaheed A. Zaki
Waheed A. Zaki
SESelwan M. El-Sayed
Selwan M. El-Sayed
MAMohamed Alswah
Mohamed Alswah
AEAhmed El-Morsy
Ahmed El-Morsy
ABAshraf H. Bayoumi
Ashraf H. Bayoumi
Kazem MahmoudKazem Mahmoud
Kazem Mahmoud
CDK2 is a key player in cell cycle processes. It has a crucial role in the progression of various cancers. Hepatocellular carcinoma (HCC) and colorectal cancer (CRC) are two common cancers that affect humans worldwide. The available therapeutic options suffer from many drawbacks including high toxicity and decreased specificity. Therefore, there is a need for more effective and safer therapeutic agents. A series of new pyrazolo[3,4-d]pyrimidine analogs was designed, synthesized, and evaluated as anticancer agents against the CRC and HCC cells, HCT116, and HepG2, respectively. Pyrazolo[3,4-d]pyrimidinone derivatives bearing N5-2-(4-halophenyl) acetamide substituents were identified as the most potent amongst evaluated compounds. Further evaluation of CDK2 kinase inhibition of two potential cytotoxic compounds 4a and 4b confirmed their CDK2 inhibitory activity. Compound 4a was more potent than the reference roscovitine regarding the CDK2 inhibitory activity (IC50 values: 0.21 and 0.25 µM, respectively). In silico molecular docking provided insights into the molecular interactions of compounds 4a and 4b with important amino acids within the ATP-binding site of CDK2 (Ile10, Leu83, and Leu134). Overall, compounds 4a and 4b were identified as interesting CDK2 inhibitors eliciting antiproliferative activity against the CRC and HCC cells, HCT116 and HepG2, respectively, for future further investigations and development.

1 November 2012 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
VTVolkmar Tell
Volkmar Tell
MHMax Holzer
Max Holzer
LHLydia Herrmann
Lydia Herrmann
Kazem MahmoudKazem Mahmoud
Kazem Mahmoud
CSChristoph Schächtele
Christoph Schächtele
AHAndreas Hilgeroth
Andreas Hilgeroth